secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001490978-23-000108
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q3 revenue $42.6M (+15% YoY); net loss widens to $62M; updates guidance
--------------------------------------------------------------------------------

- Total revenue $42.6M (+15% YoY); software revenue $28.9M (+17%); drug discovery $13.7M (+11%).
- Net loss $62.0M vs $39.9M in Q3 2022; operating expenses rose 26% to $79.8M.
- Updated FY2023 guidance: software revenue growth 15-18%; drug discovery $50-70M; cash from ops expected higher.
- Pipeline: SGR-1505 healthy volunteer data due Q4; SGR-2921 Phase 1 started; PRMT5-MTA program disclosed.
- Bristol Myers Squibb returned rights to two oncology programs; company maintains ~$503M cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/0001490978-23-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/sdgr-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001490978-23-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer